IL-17 Inhibition: Emerging Perspectives in the Future Management of Axial Spondyloarthritis

This symposium took place on 12th June 2015 as part of EULAR 2015, the Annual European Congress of Rheumatology representing the official annual meeting of the European League Against Rheumatism (EULAR), in Rome, Italy

Chairperson: Atul Deodhar1
Speakers: Dirk Elewaut,2 Dominique Baeten,3 Xenofon Baraliakos4

1. Oregon Health and Science University, Portland, Oregon, USA
2. Ghent University Hospital, Ghent, Belgium
3. Clinical Immunology and Rheumatology Academic Medical Center/ University of Amsterdam, Amsterdam, Netherlands
4. Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany

Disclosure: Atul Deodhar has participated in advisory boards and received research grants from AbbVie, Amgen, Janssen, Novartis, Pfizer, and UCB. Dirk Elewaut has received a research grant, consultation fees, and speaker honoraria from AbbVie, Boehringer Ingelheim, BMS, and Merck. Dominique Baeten has received consultation fees from AbbVie, Pfizer, MSD, UCB, Janssen, Novartis, Eli Lilly, Boehringer Ingelheim, BMS, Roche, Glenmark, and Zymetech; speaker honoraria from AbbVie, Janssen, MSD, Pfizer, UCB, BMS, and Novartis; and research grants from Pfizer, MSD, UCB, Boehringer Ingelheim, and Janssen. Xenofon Baraliakos has worked as a consultant and received speaker fees from AbbVie, BMS, Boehringer Ingelheim, Celgene, Centocor, Chugai, Janssen Biologics, Novartis, Pfizer, Sandoz, UCB, and Werfen.
Acknowledgements: Writing assistance was provided by Dr Ana Rodríguez de Ledesma, apothecom scopemedical Ltd.
Support: The symposium was jointly organised and funded by Novartis Pharmaceuticals. All authors received honoraria for preparation and delivery of their presentations. The publication of this article was funded by Novartis Pharmaceuticals. The views and opinions expressed are those of the authors and not necessarily those of Novartis Pharmaceuticals.
Citation: EMJ Rheumatol. 2015;2[1]:46-54.

Meeting Summary

The meeting was opened by Prof Atul Deodhar who introduced the prevalence, epidemiology, and clinical features of axial spondyloarthritis (axSpA), and discussed the ongoing unmet needs in the management of axSpA. Prof Dirk Elewaut described the role of the interleukin-17 (IL-17) pathway in the pathogenesis of axSpA. Prof Dominique Baeten reviewed the latest clinical data from existing and emerging therapies for axSpA. Finally, Prof Xenofon Baraliakos discussed recent advances in the assessment of bone inflammation and structural damage in axSpA. Each discussion was followed by questions and answers. The meeting was concluded with an interactive final discussion between the panellists and the audience, with concluding remarks by Prof Atul Deodhar.

Download (PDF, 137KB)

Comments are closed.